Interactions of urate transporter URAT1 in human kidney with uricosuric drugs

Nephrology

Volumn 16, Issue 2, 2011, Pages 156-162

  Shin, Ho Jung ^a   Takeda, Michio ^a   Enomoto, Atsushi ^a   Fujimura, Masaaki ^a   Miyazaki, Hiroki ^a   Anzai, Naohiko ^a   Endou, Hitoshi ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

benzbromarone; URAT1; urate transporter; uricosuric drugs

Indexed keywords

6 HYDROXY 5,7 DIMETHYL 2 METHYLAMINO 4 (3 PYRIDYLMETHYL)BENZOTHIAZOLE; 6 HYDROXYBENZBROMARONE; BENZBROMARONE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GREEN FLUORESCENT PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC ANION TRANSPORTER; PROBENECID; UNCLASSIFIED DRUG; URATE; URATE TRANSPORTER 1; URICOSURIC AGENT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; IC 50; KIDNEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZBROMARONE; BENZOTHIAZOLES; BIOLOGICAL TRANSPORT; CAPTOPRIL; CELLS, CULTURED; DOGS; ENALAPRIL; INDOMETHACIN; INHIBITORY CONCENTRATION 50; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; PHENYLBUTAZONE; PROBENECID; PYRIDINES; SALICYLATES; SULFINPYRAZONE; URIC ACID; URICOSURIC AGENTS;

EID: 79551532461     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01368.x     Document Type: Article

References (30)

1. Sica DA, Schoolwerth AC,. Renal handling of organic anions and cations: Excretion of uric acid. In:, Brenner BM, (ed.). The Kidney, 6th edn. Philadelphia, PA: Saunders, 2000; 680-700.
2. Anzai N, Kanai Y, Endou H,. New insights into renal transport of urate. Curr. Opin. Rheumatol. 2007; 19: 151-7.
3. Roch-Ramel F, Werner D, Guisan B,. Urate transport in brush-border membrane of human kidney. Am. J. Physiol. 1994; 266: F797-805.
4. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-52.
5. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I,. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J. Pharmacol. Exp. Ther. 2007; 320: 211-17.
6. Babu E, Takeda M, Narikawa S, et al. Characterization of ochratoxin A transport by human organic anion transporter 4. Biochim. Biophys. Acta 2002; 1590: 64-75.
7. Price KL, Sautin YY, Long DA, et al. Human vascular smooth muscle cells express a urate transporter. J. Am. Soc. Nephrol. 2006; 17: 1791-5.
8. Babu E, Takeda M, Nishida R, et al. Interactions of human organic anion transporters with aristolochic acids. J. Pharmacol. Sci. 2010; 113: 192-6.
9. Zou SW, Zhang JC, Zhang XD, et al. Expression and localization of VCX/Y proteins and their possible involvement in regulation of ribosome assembly during spermatogenesis. Cell Res. 2003; 13: 171-7.
10. Yamada H, Kotaki H, Furitsu H, Sawada Y, Iga T,. Mechanism of the uricosuric action of the anti-inflammatory drug, E3040 used to treat inflammatory bowel disease: I; study using a rat model of hyperuricemia. Biopharm. Drug Dispos. 1999; 20: 77-83.
11. Yamada H, Kotaki H, Itoh T, Sawada Y, Iga T,. Effect of anti-inflammatory bowel disease drug, E3040, on urate transport in rat renal brush border membrane vesicles. Eur. J. Pharmacol. 2000; 406: 45-8.
12. Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J. Biol. Chem. 2008; 283: 26834-8.
13. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM,. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab. Dispos. 2000; 28: 329-34.
14. Roch-Ramel F, Guisan B, Diezi J,. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J. Pharmacol. Exp. Ther. 1997; 280: 839-45.
15. Oikawa T, Kunishima C, Adachi Y, et al. Metabolism study of benzbromarone: In vitro metabolism and pharmacokinetics in healthy volunteers. J. New. Rem. Clin. 2004; 53: 682-91.
16. de Vries JX, Walter-Sack I, Ittensohn A, Weber E,. The isolation, identification and structure of a new hydroxylated metabolite of benzbromarone in man. Xenobiotica 1989; 19: 1461-70.
17. de Vries JX, Walter-Sack I, Voss A, et al. Metabolism of benzbromarone in man: Structures of new oxidative metabolites, 6-hydroxy- and 1'-oxo-benzbromarone, and the enantioselective formation and elimination of 1'-hydroxybenzbromarone. Xenobiotica 1993; 23: 1435-50.
18. Wood SG, John BA, Chasseaud LF, et al. Metabolic fate of the thrombolytic agent, benzarone in man: Comparison with the rat and dog. Xenobiotica 1987; 17: 881-96.
19. van der Klauw MM, Houtman PM, Stricker BH, Spoelstra P,. Hepatic injury caused by benzbromarone. J. Hepatol. 1994; 20: 376-9.
20. Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J. Hepatol. 2000; 32: 874.
21. Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone treatment: A case report. J. Gastroenterol. Hepatol. 2002; 17: 625-6.
22. Tiitinen S, Nissila M, Ruutsalo HM, Isomaki H,. Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid. Clin. Rheumatol. 1983; 2: 233-6.
23. Dan T, Koga H,. Uricosurics inhibit urate transporter in rat renal brush border membrane vesicles. Eur. J. Pharmacol. 1990; 187: 303-12.
24. Leary WP, Reyes AJ,. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc. Drugs Ther. 1987; 1: 29-38.
25. Ekaratanawong S, Anzai N, Jutabha P, et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J. Pharmacol. Sci. 2004; 94: 297-304.
26. Nierenberg DW,. Competitive inhibition of methotrexate accumulation in rabbit kidney slices by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 1983; 226: 1-6.
27. Vietri M, De Santi C, Pietrabissa A, Mosca F, Pacifici GM,. Inhibition of human liver phenol sulfotransferase by nonsteroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol. 2000; 56: 81-7.
28. Thummel KE, Shen DD,. Design an optimization of dosage regimens; pharmacokinetic data. In:, Hardman JG, Limbird LE, (eds). Goodman & Guilman's The Phramacological Basis of Therapeutics, 10th edn. New York: McGraw-Hill, 2001; 1917-2023.
29. Benet LZ, Oie S, Schwartz JB,. Design an optimization of dosage regimens; pharmacokinetic data. In:, Hardman JG, Limbird LE, (eds). Goodman & Guilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill, 1996; 1707-92.
30. Ulm EH, Hichens M, Gomez HJ, et al. Enalapril maleate and a lysine analogue (MK-521) disposition in man. Br. J. Clin. Pharmacol. 1982; 14: 357-62.